TLR3 and glioblastoma: ZNF638 KD with concomitant ICI treatment significantly altered the GBM microenvironment by increasing inflammatory cytokine expression (IL2, IL7, and IP10, and IFNs) and increasing expression of dsRNA-sensing programs (RIG-I, TLR3) (Figure 8, D–F).